Phase 4
Completed N=92
Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients
Neuromuscular Blockade
Source: ClinicalTrials.gov NCT03168308 ↗
Enrolled (actual)
92
Serious AEs
5.4%
Results posted
Feb 2020
Primary outcomePrimary: Number of Hypoxic Episodes — 1; 0 episode(s)
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This prospective, randomized, double blinded study is intended to enroll a total of 92 patients undergoing thoracic surgery with general endotracheal anesthesia at Parkland Hospital. Patients will be randomized to receive either neostigmine or sugammadex for reversal of neuromuscular blockade. Merck, Inc. will supply the sugammadex through an agreement with Parkland Investigational Drug Services. Neostigmine is readily available for anesthesiologists to use and is the current standard of care for reversal of neuromuscular blockade. A standardized anesthetic protocol that is usual and customary for the type of operation the patient is having will be provided to the anesthesia teams of enrolled subjects. The remainder of the anesthetic care of the subject will not deviate from the standard of care. The surgeon, anesthesia team, postoperative recovery nurse, and research assistant will be blinded as to which reversal drug the patient receives. The only individual that will know to which drug the patient has been randomized will be the pharmacist who draws up the medication(s). A blinded research assistant will record postoperative outcomes and the patient will be followed 90 minutes postoperatively for any adverse events.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Hypoxic Episodes |
1; 0 | — |
| SECONDARY Time to Complete Reversal of Neuromuscular Blockade |
40; 10 | — |
| SECONDARY Number of Participants Who Needed Rescue Sugammadex After Initial Reversal of Neuromuscular Blockade |
5; 0 | — |
Eligibility Criteria
Inclusion Criteria
- 18-80 years old
- Undergoing non-emergent thoracic surgery
- ASA physical status classification 2 to 4
- Willing and able to consent in English or Spanish
- No personal history of neuromuscular disease
Exclusion Criteria
- Age less than 18 or older than 80
- Patient does not speak English or Spanish
- Planned postoperative intubation or ICU admission
- Allergy to sugammadex, neostigmine, glycopyrrolate, or rocuronium
- Family or personal history of malignant hyperthermia
- Patient refusal
- Monitored anesthesia care (MAC) or regional anesthesia planned
- Pregnant or nursing women
- "Stat" (emergent) cases
- Estimated creatinine clearance <30 mL/min
- Pre-existing muscle weakness of any etiology
- Patients on toremifene (a selective estrogen receptor modulator)
- Women on oral contraceptives who do not wish to use a non-hormonal method of contraception for 7 days following surgery
Data sourced from ClinicalTrials.gov (NCT03168308). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.